Ind-Swift Laboratories Limited has informed regarding Lapse of 65,00,000 Fully Convertible Warrants and Forfeiture of Upfront Amount
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories has informed stock exchanges that 65,00,000 fully convertible warrants allotted on a preferential basis on August 30, 2024 have lapsed because the holder, Saral Incorporated VCC Sub Fund 1, did not exercise the conversion option before the February 28, 2026 deadline. Of the original 2,60,00,000 warrants issued at ₹121 each, 1,95,00,000 were already converted into equity shares, while the remaining 65,00,000 lapsed. As a result, the upfront subscription amount of ₹19.66 crore (25% of the issue price) paid by the allottee stands forfeited by the company. There is no change to the company's paid-up equity share capital from this lapse.
Mixed signal for shareholders — on the positive side, the company gets to retain the forfeited ₹19.66 crore as a windfall and avoids further equity dilution from these warrants. On the negative side, the non-conversion by Saral Incorporated VCC suggests either a lack of confidence or financial difficulty at the investor's end, which may raise questions about the company's valuation perception at the time of allotment.